{
  "id": 5266950,
  "title": "Indonesian Regulator Visits Daewoong Research Center",
  "url": "https://urgent.news/2026/09/03/indonesian-regulator-visits-daewoong-research-center",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T06:54:29.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=276141"
  },
  "original_language": "en",
  "account": "A delegation from Indonesia's Food and Drug Authority (BPOM) paid a visit to Daewoong Pharmaceutical's Magok Research Center in Seoul, the hub for the company's new drug development. This visit, announced on September 28, aimed to assess the state of research and development at the center and explore potential cooperation measures between the two countries in the pharmaceutical and bio industries. The Indonesian regulatory authority's presence at the visit was due to their participation in the 2026 Global Bio Conference (GBC 2026) and the Asia-Pacific Network of National Regulatory Control Laboratories meeting.\n\nThe Magok Research Center, Daewoong Pharmaceutical's central facility for global new drug development, boasts a sprawling infrastructure consisting of three basement levels and nine above-ground floors, capable of hosting over 1,000 research personnel. During the visit, Daewoong Pharmaceutical presented its innovative drug research system and advanced infrastructure targeting the global market, proposing specific cooperation measures for product development, approval, and business expansion in Indonesia.\n\nRita Endang, a pharmaceutical expert advisor at the head of BPOM, expressed satisfaction with Daewoong Pharmaceutical's continuous research capabilities in the new drug and bio sectors. She emphasized the potential contribution to the development of local technological capabilities through continued constructive regulatory communication with pharmaceutical companies investing in Indonesia.\n\nThis interaction holds significant importance as it aligns with the Indonesian regulatory authority's efforts to bolster its international credibility. In December 2025, BPOM was recognized as a WHO Listed Authority (WLA) in the vaccine sector, highlighting the reliability of its system. Taruna Ikrar, head of BPOM, underscored the importance of developing innovative test and evaluation methods and the need for regulatory harmonization between countries, which was discussed at the GBC 2026.\n\nOver the past two decades, Daewoong Pharmaceutical has established a strong presence in Indonesia, implementing a localization strategy that includes local production, research and development, and talent development. The company is currently engaged in advanced bio sector research, including cell therapy products, in collaboration with local research institutes. The delegation's visit to the Magok Research Center is expected to serve as a catalyst for further expansion of customized local business ventures. Lee So-yoon, head of Daewoong Pharmaceutical's Approval and Patent Center, reiterated the company's commitment to developing innovative new drugs through close cooperation with global regulatory authorities, including Indonesia.",
  "summary": "A high-level delegation from the Indonesian Food and Drug Authority (BPOM) visited the Magok Research Center, the core research hub of Daewoong Pharmaceutical.Daewoong Pharmaceutical announced on Sep. 28 that a pharmaceutical delegation from the Indonesian BPOM visited the Magok Research Center in S",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}